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The Mildly Elevated Serum Bilirubin Level is Negatively Associated
with the Incidence of End Stage Renal Disease in Patients with IgA
Nephropathy
Oxidative stress plays various roles in the development and progression of IgA
nephropathy, while bilirubin is known as a potent antioxidant. We therefore hypoth-
esized that serum bilirubin would be associated with renal prognosis in IgA nephropa-
thy. The study subjects comprised 1,458 adult patients with primary IgA nephropa-
thy in Korea. We grouped patients according to the following quartile levels of biliru-
bin: <0.4 mg/dL (Q1), 0.4-0.5 mg/dL (Q2), 0.6-0.7 mg/dL (Q3), and >0.8 mg/dL (Q4).
The outcome data were obtained from the Korean Registry of end-stage renal dis-
ease (ESRD). Eighty patients (5.5%) contracted ESRD during a mean follow-up
period of 44.9 months. The ESRD incidences were 10.7% in Q1, 8.2% in Q2, 2.8%
in Q3, and 2.8% in Q4 (p<0.001). The relative risk of ESRD compared to that in
Q1 was 0.307 (95% confidence interval [CI], 0.126-0.751) in Q3 and 0.315 (95%
CI, 0.130-0.765) in Q4. The differences of ESRD incidence were greater in sub-
groups of males and of patients aged 35 yr or more, with serum albumin 4.0 g/dL or
more, with normotension, with eGFR 60 mL/min/1.73 m
2 or more, and with protein-
uria less then 3+ by dipstick test. In conclusion, higher bilirubin level was negatively
associated with ESRD incidence in IgA nephropathy.
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INTRODUCTION
As the most common glomerulonephritis worldwide, IgA
nephropathy has the potential for slowly progressive chronic
renal impairment, leading to end-stage renal disease (ESRD)
(1). Although many studies have identified the features relat-
ed to poor prognosis, no single or combination of prognos-
tic factors has been demonstrated to account for the overall
risk for ESRD in IgA nephropathy (2). Until now, no treat-
ment has been shown to modify the mesangial deposition of
IgA and the available treatment options are directed at down-
stream immune reaction to lead on to renal scaring (2).
Although the glomerular injury in IgA nephropathy is
usually provoked by IgA-induced mesangial cell activation
and complement activation (2), increased oxidative stress was
reported to play a role in the development and progression
of IgA nephropathy (3-6). The oxidative stress detected in
the reduced glutathione and hemoglobin oxidation on periph-
eral red blood cells (RBCs) and lipid peroxidation in RBCs
and plasma was increased in patients with IgA nephropathy
compared to normal controls (6), as was the immunohisto-
chemistry for intrarenal 4-hidroxy-2-nonenal as the product
of lipid peroxidation (4). The renal infiltration of polymor-
phonuclear leukocyte which has a high potential for the pro-
duction of reactive oxygen species (ROS) increased in patients
with IgA nephropathy (5). Advanced oxidation protein prod-
ucts increased in IgA nephropathy compared with that in stable
IgA nephropathy and was an independent risk factor to the
renal outcome of IgA nephropathy (3). Intrarenal immunore-
activity of heme oxygenase-1 (HO-1), which is the inducible
HO isoform that metabolizes heme to carbon monoxide, iron,
and bilirubin converted from biliverdin, also increased in
IgA nephropathy compared to that in controls (4). 
Bilirubin is not merely an end product of heme degrada-
tion but a potent antioxidant (7) which is usually mediated
by inhibition of NADPH oxidase (8), a key source of oxi-
dants in phagocytic and non-phagocytic cells, and of pro-
tein kinase C activity (9). Several studies have been published
showing the relation between serum bilirubin and oxidative
stress-mediated diseases, including coronary artery disease
(10, 11), angiotensin II-mediated hypertension (12), and
renal ischemia-reperfusion injury in vivo (13-15).
In the present study, we investigated the role of serum
bilirubin on the progression to ESRD in IgA nephropathy.
We also analyzed the data in subgroups stratified by well-
known risk factors to renal progression in IgA nephropathy
and by possible confounding factors affecting serum biliru-
bin levels, such as gender, age (16), and serum albumin, to
which unconjugated bilirubin is bound (17). 
MATERIALS AND METHODS
Study subjects
This study was approved by the Institutional Review Board
in Seoul National University Bundang Hospital and other
participated hospitals before the data were gathered. Informed
written consent was obtained from all patients. The subjects
were enrolled in the Progressive REnal disease and Medical
Informatics and gEnomics Research (PREMIER) program
sponsored by the Korean Society of Nephrology (KSN) since
August 2003. Thirty-four hospitals and clinics in Korea par-
ticipated in the PREMIER study and shared the clinical data
of 1,469 adult patients aged 18 yr or more who were diag-
nosed as primary IgA glomerulonephritis by renal biopsy from
April 1988 to May 2007. From this group, 1,458 patients
whose serum bilirubin data were available were included in
this study. We enrolled 30 (2.1%) patients diagnosed before
2000, 41 (2.8%) in 2000, 81 (5.6%) in 2001, 123 (8.4%) in
2002, 170 (11.7%) in 2003, 351 (24.1%) in 2004, 411 (28.2
%) in 2005, 209 (14.3%) in 2006, and 42 (2.9%) in 2007.
Clinical data 
The participating researchers had selected the candidate
patients and one qualified nurse, who visited every partic-
ipated institution, input the clinical data into the formatted
database on the website (http://www.gn.or.kr) at the time of
renal biopsy and during follow-up visits. We gathered the data
of age, gender, history of diabetes mellitus, and current hyper-
tension, blood pressure, serum protein, serum albumin, serum
cholesterol, serum bilirubin, alanine aminotransferase, aspartate
aminotransferase, hemoglobin, serum creatinine, proteinuria
by dipstick test, urine RBC measured by microscopic exami-
nation of urine at renal biopsy, and medication of angiotensin-
converting enzyme inhibitors (ACEI), angiotensin II type I
receptor blockers (ARB), any kind of steroid and HMG-CoA
reductase inhibitor during the follow-up period. Hyperten-
sion was defined as a systolic blood pressure (SBP) of 140
mmHg or more, diastolic blood pressure (DBP) of 90 mmHg
or more, or the taking of anti-hypertensive medication before
renal biopsy. The estimated glomerular filtration rate (eGFR)
was calculated by the modified modification of diet in renal
disease (MDRD) equation as follow (18);
eGFR (mL/min/1.73 m2)=186.3×(serum creatinine)-1.154
×(age)-0.203 (×0.742 for female)
We classified the following clinical parameters: age, with
the criterion of 35 yr, which was the median value, serum albu-
min level with 4.0 g/dL, proteinuria by dipstick test with
3+, and hematuria with urine RBC 5 or more in microscopic
examination of urine in the field of 400-fold magnification.
We grouped the patients according to the following quar-
tile levels of serum bilirubin and compared the basal charac-
teristics and ESRD incidence during the follow-up period:S24 H.J. Chin, H.J. Cho, T.W. Lee, et al.
<0.4 mg/dL (Q1), 0.4-0.5 mg/dL (Q2), 0.6-0.7 mg/dL (Q3),
and >0.8 mg/dL (Q4).
Renal outcome
The end point was the time to the first treatment for ESRD.
The ESRD data were obtained from the Korean ESRD reg-
istry, ‘‘Insan Memorial Dialysis Registry’’, of KSN (19). The
registry contained the data of patients entering into renal
replacement therapy (RRT), dialysis or transplantation, in
Korea from 1985 to April 2008. The data was reported by
providers of RRT on paper documents before 2001 and
through an on-line registry program in the KSN website
(http://www.ksn.or.kr) from 2001. The response rate to col-
lect the data from providers in Korea was 65.1% in 2001
(19) and 66.8% in 2002 (20). We searched the data based
on the unique personal identifier which all Koreans aged 18
yr or more have and identified the RRT status of patients
with IgA nephropathy. 
Statistical analysis 
The SPSS (SPSS version 12.0, Chicago, IL, U.S.A.) package
was used for statistical analysis. Differences in proportions
among groups were compared by chi-square test. Group
differences for continuous variables were assessed by the Stu-
dent t-test or One-way ANOVA test according to the num-
ber of groups. We compared the cumulative incidence of
ESRD by Log-rank test. To determine whether the biliru-
bin level was independently related to the incidence of ESRD,
we used the Cox’s hazard proportional analysis adjusted for
age, gender, and univariate risk factors to the incidence of
ESRD. We repeated the analyses after stratification by gen-
der, age and serum albumin, which are the important factors
associated with the serum level of bilirubin, and by hyper-
tension, urine protein level and eGFR, which are the well-
known prognostic factors of IgA nephropathy. Two-sided p
values were reported with 0.05 taken as the level of statisti-
cal significance. All data are shown as mean±standard devi-
ation or frequency per observation.
RESULTS 
The basal characteristics of patients according to bilirubin
levels
The mean values of age, SBP, serum protein, serum albu-
Completeness 
of data (%)
Bilirubin groups
Q1 (n=224) Q2 (n=391) Q3 (n=386) Q4 (n=457) p value
Age (yr) 100.0 39.5/13.2
3 37.8/14.3
2,3 36.6/14.0
1,2 35.3/12.6
1 0.001
Gender (female %) 100.0 58.9 51.4 45.3* 30.0* <0.001
Current smoking (%) 91.8 9.3 13.0 14.8 16.7 0.076
History of DM (%) 92.5 2.3 1.9 4.8 4.0 0.122
Hypertension (%) 90.4 44.8 48.0 44.2 42.5 0.505
SBP (mmHg) 94.3 128/20
3 128/19
2,3 125/17
1,2 125/16
1 0.018
DBP (mmHg) 94.3 81/13 80/13 79/12 79/11 0.264
Glucose (mg/dL) 90.4 104/21 102/23 101/28 100/27 0.239
Protein (g/dL) 99.1 6.2/1.0
1 6.5/0.9
2 6.7/0.8
3 6.9/0.6
4 <0.001
Albumin (g/dL) 99.4 3.4/0.7
1 3.7/0.7
2 3.9/0.6
3 4.0/0.5
4 <0.001
Bilirubin (mg/dL) 100.0 0.3/0.1
1 0.5/0.1
2 0.7/0.1
3 1.1/0.6
4 <0.001
AST (U/L) 97.6 20/9
1 21/11
1,2 21/10
1,2 23/19
2 0.052
ALT (U/L) 99.8 17/12
1 19/17
1,2 20/17
1,2 23/57
2 0.054
Cholesterol (mg/dL) 95.1 217/97
2 195/58
1 190/52
1 188/119
1 <0.001
Hemoglobin (g/dL) 99.1 11.8/2.2
1 12.3/2.1
2 13.0/1.9
3 13.7/1.8
4 <0.001
Creatinine (mg/dL) 99.9 1.5/1.5
2 1.6/1.4
2 1.3/1.0
1 1.2/0.8
1 0.001
eGFR (mL/min/1.73 m
2) 99.9 67/38
1 71/32
1 77/30
2 82/30
2 <0.001
Proteinuria ≥3+ (%) 95.2 31.6 22.6* 22.7* 15.2* <0.001
Hematuria (%) 95.5 92.9 88.9 89.9 85.4* 0.029
Medication (%)
ACEI or ARB 100.0 60.3 51.7* 53.1 54.7 0.207
Statin 100.0 21.4 13.8* 14.0* 9.6* <0.001
Table 1. The characteristics of patients at renal biopsy
*, Difference of frequency compared to Q1 bilirubin group, p<0.05, number/number: mean/standard deviation.
Number right upper side of data: Duncan post hoc analysis in One-Way ANOVA test.
DM, diabetes mellitus; AST, aspartate aminotransferase; ALT, alanine aminotransferase; proteinuria ≥3+, proteinuria 3+ or more by dipstick test; hema-
turia, urine RBC 5 or more by microscopic examination of urine in a filed of 400-fold magnification; ACEI or ARB, angiotensin converting enzyme inhibitor
or angiotensin II type I receptor blocker; Statin, HMG-Co reductase inhibitor.Bilirubin and IgA Nephropathy S25
min, serum cholesterol, serum creatinine, eGFR, and hemo-
globin differed among the bilirubin groups (Table 1). The
mean values of age, SBP, serum cholesterol and serum crea-
tinine were lower, but those of serum protein, serum albumin,
eGFR and hemoglobin were higher, in patients with higher
bilirubin level. The frequencies of being female, having pro-
teinuria 3+ or more, having hematuria, and using statin
were higher in patients with lower serum bilirubin level. 
The risk factors to the incidence of ESRD in IgA
nephropathy
Eighty of the 1,458 patients (5.5%) contracted ESRD
during a mean follow-up period of 44.9 months (SD: 22.3
months). The overall renal survival rate was 98.6% at 1 yr,
93.2% at 5 yr, and 80.7% at 10 yr after renal biopsy. The
incidences of ESRD were 10.7% in Q1, 8.2 % in Q2, 2.8%
in Q3, and 2.8% in Q4 (p<0.001). The mean follow-up
period was not different among the bilirubin groups (p>0.05).
The numbers of patients followed at renal biopsy, at 1, 2, 3,
4, and 5 yr after renal biopsy were 224, 215, 179, 120, 53,
and 36 in Q1, 391, 372, 324, 224, 113, and 79 in Q2, 386,
381, 328, 232, 146, and 92 in Q3, and 457, 450, 403, 283,
152, and 93 in Q4, respectively. The probability of ESRD
was the highest in Q1 among the bilirubin groups, as shown
in Fig. 1.
The age, SBP, DBP, serum protein, serum albumin, serum
bilirubin, hemoglobin, serum creatinine and eGFR, and the
frequencies of hypertension, proteinuria 3+or more, and the
usage of steroids were the univariate factors for the incidence
of ESRD (Table 2). In Cox’s hazard proportional model adjust-
ed for gender and univariate risk factors, the bilirubin group
was one of the independent risk factors for ESRD (Table 3).
The relative risk (RR) of ESRD compared to that in Q1 was
0.307 (95% confidence interval [CI], 0.126-0.751) in Q3 and
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Fig. 1. The probability of renal survival according to serum biliru-
bin level at renal biopsy.
Q1, First quartile group; Q2, Second quartile group; Q3, Third
quartile group; Q4, Forth quartile group.
No-ESRD
(n=1,378)
ESRD
(n=80)
p value
Age (yr) 36/14 40/14 0.022
Gender (female %) 44.8 35.0 0.087
Current smoking (%) 13.9 16.7 0.531
History of DM (%) 3.2 7.4 0.066
Hypertension (%) 43.3 72.7 <0.001
SBP (mmHg) 126/17 137/26 <0.001
DBP (mmHg) 79/12 85/16 <0.001
Glucose (mg/dL) 101/25 104/31 0.481
Protein (g/dL) 6.7/0.8 6.0/1.0 <0.001
Albumin (g/dL) 3.8/0.6 3.2/0.6 <0.001
Bilirubin (mg/dL) 0.7/0.5 0.5/0.4 0.002
AST (U/L) 21/13 21/17 0.848
ALT (U/L) 21/36 19/21 0.781
Cholesterol (mg/dL) 193/71 226/226 0.198
Hemoglobin (g/dL) 13.0/2.0 10.7/2.2 <0.001
Creatinine (mg/dL) 1.2/0.9 3.0/2.6 <0.001
eGFR (mL/min/1.73 m
2) 77.7/31.3 35.7/21.0 <0.001
Proteinuria ≥3+ (%) 21.0 33.8 0.010
Hematuria (%) 88.7 87.7 0.785
Medication (%)
ACEI or ARB 54.8 46.3 0.136
Statin 13.6 16.3 0.498
Table 2. The difference of basal characteristics according to
renal progression to end-stage renal disease (ESRD)
Number/number, mean/standard deviation.
DM, diabetes mellitus; AST, aspartate aminotransferase; ALT, alanine
aminotransferase; proteinuria ≥3+, proteinuria 3+ or more by dipstick
test; hematuria, urine RBC 5 or more by microscopic examination of
urine in a filed of 400-fold magnification; ACEI or ARB, angiotensin con-
verting enzyme inhibitor or angiotensin II type I receptor blocker; Statin,
HMG-Co reductase inhibitor.
Variables B Wald p value OR [95% C.I.]
Bilirubin Group* - 9.956 0.019 -
Q2 (0.4-0.59 mg/dL) -0.476 1.968 0.161 0.621 [0.319-1.208]
Q3 (0.6-0.79 mg/dL) -1.180 6.689 0.010 0.307 [0.126-0.751]
Q4 (≥0.8 mg/dL) -1.154 6.514 0.011 0.315 [0.130-0.765]
Hypertension 0.901 8.190 0.004 2.462 [1.328-4.563]
Serum creatinine  0.373 84.240 <0.001 1.453 [1.341-1.573]
(mg/dL)
Serum albumin (g/dL) -0.794 16.294 <0.001 0.452 [0.308-0.665]
Table 3. The independent risk factor to the incidence of end-stage
renal disease in IgA nephropathy analyzed by Cox’s hazard pro-
portional model
Adjusted with age, gender, hypertension, systolic blood pressure, dias-
tolic blood pressure, serum albumin, serum creatinine, urine protein 3+
or more by dipstick test, and bilirubin groups.
*Compared to bilirubin group, first quartile group with bilirubin less than
0.4 mg/dL.
OR, odds ratio; C.I., confidence interval.S26 H.J. Chin, H.J. Cho, T.W. Lee, et al.
0.315 (95% CI, 0.130-0.765) in Q4. The other risk factors for
ESRD were the presence of hypertension, higher serum cre-
atinine level, and lower serum albumin level at renal biopsy.
The RR for ESRD among bilirubin groups in subgroups 
We analyzed the RR for ESRD in the bilirubin groups by
Cox’s hazard proportional model adjusted with univariate
risk factors in each subgroup stratified by possible confound-
ing factors to serum bilirubin level and the renal prognosis
in IgA nephropathy. In males, the bilirubin group was a risk
factor for ESRD and the RR was decreased in Q3 and Q4
compared to that in Q1. Similarly, in patients aged 35 yr or
more, with normotension, with serum albumin 4.0 g/dL or
more, with eGFR 60 mL/min/1.73 m2 or more, or with pro-
teinuria less then 3+ by dipstick test, the RR for ESRD in
Q3 and Q4 was lower than that in Q1 (Table 4). 
DISCUSSION
In this study, we observed the incidence of ESRD and the
important role of bilirubin level on renal prognosis in a large
number of patients with IgA nephropathy in Korea. The
overall 10-yr survival rate in IgA nephropathy was reported
as about 80% (21, 22), which was comparable to the rate in
this study, although the study population and follow-up dura-
tion differed among the various studies. In a U.S.A. paper by
Radford et al., the renal survival rate was below the average
survival rate because the clinical presentation at renal biop-
sy was more advanced than in the other studies (23). 
We collected the data of renal outcome through the Kore-
an ESRD registry. In the database, it was estimated that 65%
of the total ESRD patients from institutions undergoing
RRT in Korea were registered. Although this registry did
not contain 100% of RRT data, we could estimate the effects
of bilirubin group on renal survival because the renal survival
rate was in agreement with that from other reports and the
period of renal biopsy was relatively recent in this study, even
though the necessary duration to progress to ESRD in IgA
nephropathy is known to be relatively long. In IgA nephropa-
thy, the calculated incidence of ESRD from initial presenta-
tion has been reported to be approximately 1.5% per year
and about 25 to 30% of published cohorts required RRT
within 20 to 25 yr of presentation (2). In the present study,
the frequencies of ESRD according to the diagnosed period
were 14.1% before 2001, 12.3% in 2001, 4.1% in 2002,
5.9% in 2003, 6.8% in 2004, 3.4% in 2005, and 2.8% after
2005. These data indicated that the possible error due to
incomplete data in estimating renal survival would be less
Stratified subgroups
Relative risk to the incidence of ESRD in bilirubin groups*
Q1 Q2 Q3 Q4 p value
Gender subgroups
Male
� Ref. 0.708 [0.303-1.655] 0.242 [0.075-0.779] 0.310 [0.111-0.869] 0.035
Female Ref. --- 0.289
Age subgroups (yr)
Age <35 Ref. --- 0.073
Age ≥35
� Ref. 0.369 [0.160-0.852] 0.316 [0.126-0.795] 0.189 [0.067-0.534] 0.004
Hypertension subgroups
Normotension
� Ref. 0.573 [0.173-1.893] 0.067 [0.007-0.629] 0.097 [0.012-0.807] 0.023
Hypertension Ref. --- 0.095
eGFR subgroups (mL/min/1.73 m
2)
eGFR ≥60
‖ Ref. 0.577 [0.169-1.970] 0.237 [0.055-1.029] 0.053 [0.006-0.454] 0.028
eGFR <60 Ref. --- 0.118
Albumin subgroups (g/dL)
Albumin ≥4.0
¶ Ref. 0.995 [0.552-1.791] 0.388 [0.180-0.836] 0.380 [0.176-0.824] 0.006
Albumin <4.0 Ref. --- 0.417
Proteinuria subgroups (by dipstick test)
Proteinuria <3+** Ref. 0.322 [0.132-0.785] 0.169 [0.057-0.499] 0.120 [0.038-0.379] <0.001
Proteinuria ≥3+ Ref. --- 0.074
Table 4. The relative risk to ESRD in patients with IgA nephropathy after stratification with clinical parameters analyzed by Cox’s haz-
ard proportional model
*: Compared to bilirubin group, first quartile group with bilirubin less than 0.4 mg/dL, ref.: reference group; 
� : Model adjusted with age, hypertension,
SBP, serum albumin, serum creatinine, proteinuria 3+ or more, and bilirubin groups which were univariate factors to ESRD in this subgroup; 
� : Model
adjusted with gender, hypertension, SBP, DBP, serum albumin, serum creatinine, and bilirubin groups which were univariate factors to ESRD in this
subgroup; 
�: Model adjusted with age, serum albumin, serum creatinine, proteinuria 3+ or more, and bilirubin groups which were univariate factors to
ESRD in this subgroup; 
‖: Model adjusted with serum albumin, serum creatinine, and bilirubin groups which were univariate factors to ESRD in this
subgroup; 
¶: Model adjusted with gender, age, and bilirubin groups which were univariate factors to ESRD in this subgroup, **: Model adjusted with
diabetes mellitus, hypertension, SBP, DBP, serum albumin, serum creatinine, and bilirubin groups which were univariate factors to ESRD in this sub-
group.Bilirubin and IgA Nephropathy S27
significant in patients with a short duration of disease. Fur-
thermore, if we defined renal progression as a doubling or
more of serum creatinine level at follow-up compared to that
at renal biopsy, then the RR to renal progression compared
to that in Q1 was 0.419 (95% CI, 0.189-0.930) in Q3 and
0.205 (95% CI, 0.075-0.562) in Q4 and the bilirubin group
was an independent prognostic factor to renal progression
(p=0.013 by Cox’s hazard progression model adjusted with
univariate factors to a doubling or more of serum creatinine)
among the 1,031 patients who had repeated serum creati-
nine values in this study.
The generally accepted renal prognostic factors in clinical
characteristics are age, severity of proteinuria, hypertension,
and impaired renal function (reviewed in 2). However, as
these factors do not completely account for the risk for ESRD
in IgA nephropathy (2), it is important to define new mark-
ers for estimating renal prognosis and for developing a new
therapeutic modality in IgA nephropathy. There were few
reports on the role of serum bilirubin in chronic renal dis-
ease, including glomerulonephritis. In addition to the tradi-
tional prognostic factors to renal progression, we revealed
that the serum bilirubin level at renal biopsy was an impor-
tant prognostic factor for ESRD. A serum bilirubin level of
0.6 mg/dL or more (i.e., the bilirubin level in Q3 and Q4)
was associated with a lower incidence of ESRD, which is
similar to the serum bilirubin level of 10 μ M/L used as a cut-
off point for the discrimination of cardiovascular risk in other
studies (10).
Increased oxidative stress was reported to affect the devel-
opment and progression of IgA nephropathy (3-6), although
glomerular injury in IgA nephropathy is usually provoked
by IgA-induced mesangial cell activation and complement
activation (2). Several laboratory investigations have provid-
ed a biological background to explain the anti-oxidant and
anti-inflammatory effects of bilirubin. Although bilirubin
was known to scavenge peroxyl radicals in an in vitro study
(7), the antioxidant effect of bilirubin is usually mediated
by inhibition of NADPH oxidase (8) and protein kinase C
activity (9). Increased endothelial NADPH oxidase activity
is a key mediator of atherosclerosis, including glomeruloscle-
rosis (24, 25), and activation of NADPH oxidase appears to
play a key role in TGF-beta signaling and in the responsive-
ness of collagen synthesis (26, 27), which is a common path-
way to glomerulosclerosis in various types of glomerulonephri-
tis. The other possibilities to explain the effect of bilirubin
on the prognosis of IgA nephropathy are the inverse relation-
ship of bilirubin to insulin resistance, metaolic syndrome
(28) and the atherosclerosis (10, 11). It is well known that
the chronic kidney disease including IgA nephropathy is
related to insulin resistance and atherosclerosis. The benefi-
cial effect of bilirubin on the prognosis might not be related
to the pathogenetic process of IgA nephropathy per se but
related to atherosclerosis or insulin resistance which is man-
ifested in IgA nephropathy. But, considering bilirubin was
reported to inhibit antigen-specific and polyclonal T cell
responses at multiple steps in recent report (29), bilirubin
might also have some roles on the immune regulation in the
IgA nephropathy which remains to be verified.
Although the reason that the relation between bilirubin
and renal prognosis in IgA nephropathy was only evident in
the male group was not elucidated, the gender effect on the
heme oxygenase inducibility to stress, which is the rate-lim-
iting enzyme to produce bilirubin, would be considerable.
Trauma and hemorrhage doubled the hepatic HO-1 expres-
sion in female rats compared with male rats (30). The biliru-
bin effect on renal progression may have been overwhelmed
by further severe risk factors such as hypertension, massive
proteinuria, or renal impairment, which was in agreement
with the finding that the bilirubin group was only a prog-
nostic factor among patients with normotension, with serum
albumin 4.0 g/dL or more, with proteinuria less then 3+ by
dipstick test, or with eGFR 60 mL/min/1.73 m2 or more. 
This study suffered several limitations on the generaliz-
ability of the results. We had no information on hormonal
replacement and the menopausal status, although the mean
age of women in this study was younger than the average
age of menopause in Korean women, 47 yr, or on fasting
status, which affected the level of serum bilirubin. As men-
tioned above, we could not guarantee 100% of participation
rate of RRT providers in gathering information about ESRD
and could not estimate the rate of RRT abandonment in
newly diagnosed ESRD patients. The data in this study were
from many institutions and might have inter-institutional
variation according to the devices to measure biological param-
eters, such as, bilirubin. This limitation may act as a con-
founding factor to the relation between bilirubin group and
renal prognosis. 
Nevertheless, our results have revealed that serum biliru-
bin level is an important new prognostic factor for renal prog-
nosis in a large cohort of IgA nephropathy. This finding sug-
gests the importance of oxidative stress in renal progression
and strengthens the possible therapeutic role of antioxidants
in IgA nephropathy.
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